0001144204-16-140105.txt : 20161219 0001144204-16-140105.hdr.sgml : 20161219 20161219060418 ACCESSION NUMBER: 0001144204-16-140105 CONFORMED SUBMISSION TYPE: 25 PUBLIC DOCUMENT COUNT: 1 FILED AS OF DATE: 20161219 DATE AS OF CHANGE: 20161219 EFFECTIVENESS DATE: 20161219 FILER: COMPANY DATA: COMPANY CONFORMED NAME: NORTHWEST BIOTHERAPEUTICS INC CENTRAL INDEX KEY: 0001072379 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 943306718 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 25 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35737 FILM NUMBER: 162057737 BUSINESS ADDRESS: STREET 1: 4800 MONTGOMERY LANE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 BUSINESS PHONE: (240) 497-9024 MAIL ADDRESS: STREET 1: 4800 MONTGOMERY LANE STREET 2: SUITE 800 CITY: BETHESDA STATE: MD ZIP: 20814 25 1 v455184_25.htm FORM 25

 

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D. C. 20549

 

FORM 25

 

NOTIFICATION OF REMOVAL FROM LISTING AND/OR

REGISTRATION UNDER SECTION 12(b) OF THE

SECURITIES EXCHANGE ACT OF 1934.

 

Commission File Number:    001-35737

 

 

Northwest Biotherapeutics, Inc.                                              The NASDAQ Capital Market

(Exact name of Issuer as specified in its charter, and name of Exchange where security is listed and/or registered
         4800 Montgomery Lane, Suite 800, Bethesda, MD 20814                          (204) 497-9024
(Address, including zip code, and telephone number, including area code, of Issuer's principal executive offices)
Common Stock, par value $0.001 per share; Warrants to purchase Common Stock
(Description of class of securities)

Please place an X in the box to designate the rule provision relied upon to strike the class of securities from listing and registration:

¨       17 CFR 240.12d2-2(a)(1)

¨       17 CFR 240.12d2-2(a)(2)

¨       17 CFR 240.12d2-2(a)(3)

¨       17 CFR 240.12d2-2(a)(4)

¨       Pursuant to 17 CFR 240.12d2-2(b), the Exchange has complied with its rules to strike the class of securities from listing and/or withdraw registration on the Exchange.1

x       Pursuant to 17 CFR 240.12d2-2(c), the Issuer has complied with the rules of the Exchange and the requirements of 17 CFR 240.12d2-2(c) governing the voluntary withdrawal of the class of securities from listing and registration on the Exchange.

 

 

 

 

 

 

 

 

 

 

 

1 Form 25 and attached Notice will be considered compliance with the provisions of 17 CFR 240.19d-1 as applicable. See General Instructions.

 

 

 

 

Pursuant to the requirements of the Securities Exchange Act of 1934, Northwest Biotherapeutics, Inc. certifies that it has reasonable grounds to believe that it meets all of the requirements for filing the Form 25 and has caused this notification to be signed on its behalf by the undersigned duly authorized person.

 

Date: December 19, 2016 By:  NORTHWEST BIOTHERAPEUTICS, INC.
   
              By: /s/ Linda F. Powers            
              Name: Linda F. Powers
              Title: Chief Executive Officer